HARBIN, China, Sept. 10 CSY-26-New-Drugs
HARBIN, China, Sept. 10 /Xinhua-PRNewswire-FirstCall/ -- China Sky One
Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY), a
leading fully integrated pharmaceutical company producing over-the-counter
drugs in the People's Republic of China ("PRC"), announced today that it
successfully developed 26 new drugs that are currently in clinical trials.
Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), a
wholly-owned subsidiary of China Sky One Medical, recently completed research
and development for the 26 new drugs, which have been submitted to the State
Food and Drug Administration (SFDA) in the PRC for approval.
-- Four drugs, including Cleaning suppositories, Tinidazole
suppositories, Policresulen vaginal suppositories, and Aciclover gel
are for the treatment of vaginits;
-- Three drugs, including Chlorhexidine Gluconate, Cetylpyridinium
Chloride and Compound Chlorhexidine, are gargles for the treatment
of toothache;
-- Three drugs, including Diclofenac Sodium Suppositories, Paediatric
Ibuprofen suppositories and Musky cream, are for pain relief;
-- Three drugs, including Hydroxybenzene gel, Podophyllotoxin Tincture
and Nitrofurantoin suppositories, are anti-infectives;
-- Two drugs, including Collunarium and Compound Naphazoline Spray, are
for the treatment of rhinopathy;
-- Two drugs, including Sulfasalazine suppositories and Sodium ferulate
injection are for the treatment of cardiovascular disease;
-- Methionine Vitamin B1 injection is for improving liver function;
-- Doxofylline injection is for the treatment of asthma;
-- Pantoprazole sodium injection is for the treatment of canker sores;
-- Calcium Folinate injection is intended as an antidote for folic acid
deficiency;
-- Hydrastis suppositories are for the treatment of colds; and
-- The final four drugs, including hemorrhoids gel, hemorrhoids liquids,
chilblain cream and expectorant, are all externally used.
"We are excited about the potential for our new drugs currently in
clinical trials and we believe that our advanced R&D capabilities will
continue to help us expand our market share," said Mr. Yan-Qing Liu, Chairman,
CEO and President of China Sky One Medical. "We estimate that the new drugs
will account for a 30% increase in our 2009 revenues if production approval is
received by the end of the year."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.
The Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its
wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology
Company, Harbin First Bio-Engineering Company Limited, and Heilongjiang
Tianlong Pharmaceutical, Inc., the Company manufactures and distributes over-
the-counter pharmaceutical products, which make up its major revenue source.
For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by the use
of forward- looking terminology such as "believe," "expect," "may," "will,"
"should," "project," "plan," "seek," "intend," or "anticipate" or the negative
thereof or comparable terminology. Such statements typically involve risks
and uncertainties and may include financial projections or information
regarding our future plans, objectives or performance. Actual results could
differ materially from the expectations reflected in such forward-looking
statements as a result of a variety of factors, including the risks associated
with the effect of changing economic conditions in The People's Republic of
China, variations in cash flow, reliance on collaborative retail partners and
on new product development, variations in new product development, risks
associated with rapid technological change, and the potential of introduced or
undetected flaws and defects in products, and other risk factors detailed in
reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Yu-bo Hao, Board Secretary
Tel: +86-0451-5399-4069
Email: china_sky_one@yahoo.cn
Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Mr. Richard Micchelli, Financial Writer
Tel: +1-646-454-4516
Email: richard.micchelli@ccgir.com
Web: http://www.ccgir.com
SOURCE China Sky One Medical, Inc.
